|
[posting]56492489[/posting] Axsome Therapeutics (AXSM) Market Cap: $120 M Cash $40 M Price: $4.75 Anticipated Near-Term Clinical Milestones • Clinical Trial Readouts: Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (late December 2017 to early January 2018) Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (late December 2017 to early January 2018) Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1H 2018) |
|
| aus der Diskussion: | AXSM (Mkap $83 M) (Cash $40 M) 4 x Phase 3 Studien /erste Daten im 2H 2017 |
| Autor (Datum des Eintrages): | Biohero (20.12.17 19:57:13) |
| Beitrag: | 144 von 268 (ID:56509028) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |